|
E. Edward Baetge, Ph.D., became vice president and chief scientific officer when Novocell merged with CyThera and Bresagen Inc. in 2004. He was recruited to CyThera, as chief scientific officer in 2001 to head its then emerging human embryonic stem cell program. Prior to joining CyThera, Dr. Baetge held the position of chief scientific officer at Modex Therapeutics Ltd., in Lausanne, Switzerland, which developed one of the first adult stem cell products for the treatment of chronic ulcers culminating in a $64 million initial public offering. Before Modex, Dr. Baetge held management positions at CytoTherapeutics and Bristol-Myers Squibb. He holds a Ph.D. in molecular neurobiology from Cornell University and completed postdoctoral work at Cornell University and the Howard Hughes Medical Institute. Dr. Baetge has published extensively in the field of cell therapy and produced a number of cell technology patents. | 